Myelodysplastic Syndrome Treatment Market, by Drug (Lenalidomide, Decitabine, Azacitidine, and Phase 3 Drugs), by Route of Administration (Injection and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022

Code : CMI775

Pages :182

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Myelodysplastic Syndrome (MDS) Treatment Market: Restraint

The major factors that hinder growth of the global myelodysplastic syndrome (MDS) treatment market include high cost of treatment for Myelodysplastic Syndrome (MDS). For instance, in January 2018, according to the National Center for Biotechnology Information, myelodysplastic syndromes (MDS) encompass a range of myeloid neoplasms characterized by a defect in haematopoietic stem cell maturation, resulting in peripheral cytopenias. As a major consequence, most MDS patients become anemic, so as to require red blood cell transfusions. From Medline and Embase, 742 studies were identified, of which 17 were considered eligible. Total medical costs per patient/year range from US$ 9,840 to US$ 19,811 for the transient ischaemic attack (TI) condition and from US$ 29,608 to US$ 51,066 in Myelodysplastic Syndrome (MDS).

Increasing regulatory approval of drugs for treating Myelodysplastic Syndrome (MDS) is expected to be a driving factor contributing to growth of the global myelodysplastic syndrome treatment market over the forecast period.

Increasing regulatory approval for the drugs used in the treatment of Myelodysplastic Syndrome (MDS) treatment is expected to drive the market growth over the forecast period. For instance, in November 2018, Lupin received the U.S. Food and Drug Administration approval for its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is indicated for the treatment of patients with myelodysplastic syndromes (MDS), which includes previously treated and untreated, de novo, and secondary MDS of all French-American-British subtypes.

Moreover, in July 2020, the U.S. Food and Drug Administration approved Inqovi (decitabine and cedazuridine) tablets for treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This represents an important advancement in treatment options for patients with myelodysplastic syndrome (MDS), a type of blood cancer, who previously used to receive intravenous therapy.